1. ¹INSERM UMR S 956, Paris, France
2. ²University Paris6, Pierre et Marie Curie, Paris, France
3. ³Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
4. ⁴Université Pierre et Marie Curie-Paris6, INSERM IFR CMV, Paris, France
5. ⁵Cardiothoracic Surgery Department, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

Correspondence: Jean-Sébastien Hulot, Laboratoire de Pharmacologie/INSERM U956, Faculté de Médecine Pitié-Salpêtrière, 91, Bvd de l'hôpital, 75013, Paris. E-mail: jean-sebastien.hulot@psl.ap-hop-paris.fr

Received 6 August 2008; Accepted 3 December 2008; Published online 23 December 2008.

Abstract

Our objective was to study the expression and function of stromal interaction molecule 1 (STIM1), an endoplasmic reticulum protein recently identified as the calcium sensor that regulated Ca²⁺-released activated channels in T cells. STIM1 was found to be upregulated in serum-induced proliferating human coronary artery smooth muscle cells (hCASMCs) as well as in the neointima of injured rat carotid arteries. Growth factors–induced proliferation was significantly lower in hCASMC transfected with STIM1 siRNA than in those transfected with scrambled siRNA (increase relative to 0.1% S: 116 12% and 184 16%, respectively, P < 0.01). To assess the role of STIM1 in preventing vascular smooth muscle cells (VSMCs) proliferation in vivo, we infected balloon-injured rat carotid arteries with an adenoviral vector expressing a short hairpin (sh) RNA against rat STIM1 mRNA (Ad-shSTIM1). Intima/media ratios reflecting the degree of restenosis were significantly lower in Ad-shSTIM1- infected arteries than in Ad-shLuciferase-infected arteries (0.34 0.02 vs. 0.92 0.11, P < 0.006). Finally, we demonstrated that silencing STIM1 prevents activation of the transcription factor NFAT (nuclear factor of activated T cell). In conclusion, STIM1 appears as a major regulator of in vitro and in vivo VSMC proliferation, representing a novel and original pharmacological target for prominent vascular proliferative diseases.